for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brooklyn Immunotherapeutics Inc

BTX.A

Latest Trade

18.75USD

Change

-2.85(-13.19%)

Volume

287,629

Today's Range

18.20

 - 

23.20

52 Week Range

1.90

 - 

80.67

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
21.60
Open
21.74
Volume
287,629
3M AVG Volume
116.64
Today's High
23.20
Today's Low
18.20
52 Week High
80.67
52 Week Low
1.90
Shares Out (MIL)
1.49
Market Cap (MIL)
897.74
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Ault Global Holdings Acquires 9.96% Equity Interest In Ntn Buzztime

NTN Buzztime Announces Date Of Special Meeting Of Stockholders To Vote On Proposed Merger, Asset Sale

Ault Global Holdings Inc Reports Stake Of 9.96% In Ntn Buzztime As Of Jan 26,2021 - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brooklyn Immunotherapeutics Inc

Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.

Industry

Business Services

Contact Info

140 58Th Street, Building A, Suite 2100

BROOKLYN, NY

92009

United States

+1.212.5821199

https://www.buzztime.com/

Executive Leadership

Luba Greenwood

Chairman of the Board

Howard J. Federoff

President, Chief Executive Officer

Lynn Sadowski Mason

Executive Vice President - Clinical Development

Ronald Guido

Chief Development Officer

Charles Cherington

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
154.78
Price To Book (MRQ)
37.69
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
241.36
LT Debt To Equity (MRQ)
62.51
Return on Investment (TTM)
-93.79
Return on Equity (TTM)
-49.41

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up